Contact Us
Drug Search Results
More Filters [+]

Levosulpiride

Alternative Names: levosulpiride
Latest Update: 2024-12-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: D2 Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Bulgaria | Chile | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | India | Italy | Korea | Lebanon | Malta | Mexico | Pakistan | Peru | Portugal | Romania | Saudi Arabia | Spain | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hainan Tianya Pharmaceutical Co., Ltd./Shanghai Huatuo Pharmaceutical Technology Development Co., Ltd./Hainan Sihuan Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Levosulpiride

Countries in Clinic: Unknown Location

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Depressive Disorder|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20160303

P2

Not yet recruiting

Schizophrenia|Depressive Disorder

None

Recent News Events

Date

Type

Title

03/20/2024

PubMed

 Dopaminergic Drugs and Valproate-associated Refractory Hyponatremia Over Levosulpiride-induced Parkinsonism in an Elderly Female Patient When Deprescribing was the Only Therapy.

01/01/2024

PubMed

 Fixed drug combination (levosulpiride and rabeprazole)-induced atypical Parkinsonian's disorders with associated anxiety and low-lying depression.

09/02/2023

News Article

 The Levosulpiride market report's foreign opportunities and dynamics analysis delves into the market's size, which is projected to grow at a CAGR of 8.5% from 2023 to 2030, and provides an overview of revenue generation, COVID-19 impact, and application.

09/02/2023

News Article

 Strontium Chloride Hexahydrate Market Trends identifies the leading companies and provides analysis of key factors influencing t 4% CAGR Forecasted from 2023 to 2030

09/02/2023

News Article

 This report provides a comprehensive analysis of the Cancer Pain market's current state and future growth potential, with a projected CAGR of 4.4% over the forecast period 2023 to 2030.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions